These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 6377501)
21. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy. Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342 [TBL] [Abstract][Full Text] [Related]
22. Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Tamaki H; Ikegame K; Kawakami M; Fujioka T; Tsuboi A; Oji Y; Oka Y; Sugiyama H; Kawase I; Ogawa H Leukemia; 2003 Oct; 17(10):2052-4. PubMed ID: 14513058 [No Abstract] [Full Text] [Related]
23. Cytokine network in peripheral blood mononuclear cells after allogeneic bone marrow transplantation. Tanaka J; Imamura M; Kasai M; Hashino S; Kobayashi S; Noto S; Sakurada K; Asaka M Transplant Proc; 1996 Jun; 28(3):1746-7. PubMed ID: 8658865 [No Abstract] [Full Text] [Related]
24. Diminishing morbidity and mortality of bone marrow transplantation. Tutschka PJ Vox Sang; 1986; 51 Suppl 2():87-94. PubMed ID: 3020798 [TBL] [Abstract][Full Text] [Related]
25. Bone marrow transplantation with T-cell depleted allografts for the treatment of severe beta thalassemia major. Or R; Naparstek E; Aker M; Cividalli G; Engelhard D; Brautbar C; Weshler Z; Weiss L; Mumcuoglu M; Rachmilewitz EA Prog Clin Biol Res; 1989; 309():217-22. PubMed ID: 2675089 [No Abstract] [Full Text] [Related]
26. Role of immunosuppressive drugs for prevention of graft-v-host disease after human HLA matched bone marrow transplantation. Gluckman E; Devergie A; Lokiec F; Traineau R; Cosset JM; Lemercier N; Varrin F; Cavazzana M; de Castro H; Meletis J Transplant Proc; 1987 Dec; 19(6 Suppl 7):61-5. PubMed ID: 3321648 [No Abstract] [Full Text] [Related]
27. Bone marrow transplantation for thalassemia in Pescara. Di Bartolomeo P; Di Girolamo G; Angrilli F; Catinella V; Ciancarelli M; Dragani A; D'Antonio D; Palka G; Guanciali-Franchi P; Iacone A Prog Clin Biol Res; 1989; 309():193-9. PubMed ID: 2675086 [No Abstract] [Full Text] [Related]
28. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). Kröger N; Einsele H; Wolff D; Casper J; Freund M; Derigs G; Wandt H; Schäfer-Eckart K; Wittkowsky G; Schmitz N; Krüger W; Zabelina T; Renges H; Ayuk F; Krüll A; Zander A; Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047 [TBL] [Abstract][Full Text] [Related]
29. Bone marrow transplantation in thalassemia. The experience of Pesaro. Lucarelli G; Galimberti M; Polchi P; Angelucci E; Baronciani D; Giardini C; Manenti F; Politi P; Durazzi SM; Albertini F Prog Clin Biol Res; 1989; 309():163-71. PubMed ID: 2675083 [No Abstract] [Full Text] [Related]
34. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Chemnitz JM; von Lilienfeld-Toal M; Holtick U; Theurich S; Shimabukuro-Vornhagen A; Krause A; Brossart P; Hallek M; Scheid C Ann Hematol; 2012 Jan; 91(1):47-55. PubMed ID: 21584670 [TBL] [Abstract][Full Text] [Related]
35. Regeneration of genetically restricted immune functions after human bone marrow transplantation: influence of four different strategies for graft-v-host disease prophylaxis. Donnenberg AD; Hess AD; Duff SC; Bright EC; Noga SJ; Rowley SD; Saral R; Santos GW Transplant Proc; 1987 Dec; 19(6 Suppl 7):144-52. PubMed ID: 3321641 [No Abstract] [Full Text] [Related]
36. [Bone marrow transplantation for severe aplastic anemia]. Bullorsky EO; Bonduel M; Shanley C; Figueroa C; Stemmelin G; Del Pozo A; Ceresetto J; Delfino S; Puppo M; Muriel FS Medicina (B Aires); 1998; 58(2):130-4. PubMed ID: 9706244 [TBL] [Abstract][Full Text] [Related]
37. Bone marrow transplantation from unrelated donors for genetic diseases following conditioning with Busulphan and Cyclophosphamide. Vellodi A; Jurges E; el-Tumi M; Abdul-Ahad A; Hobbs JR Bone Marrow Transplant; 1991; 7 Suppl 2():70. PubMed ID: 1878726 [No Abstract] [Full Text] [Related]
38. Myeloablative conditioning for marrow transplantation in myelodysplastic syndromes and paroxysmal nocturnal haemoglobinuria. Kolb HJ; Holler E; Bender-Götze C; Walther U; Mittermüller J; Clemm C; Bauchinger M; Gerhartz HH; Brehm G; Ledderose G Bone Marrow Transplant; 1989 Jan; 4(1):29-34. PubMed ID: 2647184 [TBL] [Abstract][Full Text] [Related]
39. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871 [TBL] [Abstract][Full Text] [Related]
40. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment. Glass B; Uharek L; Gaska T; Gassmann W; Löffler H; Müller-Ruchholtz W Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]